ReviewToxins2018
The Expanding Therapeutic Utility of Botulinum Neurotoxins.
Review in Toxins, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Benefits of Incobotulinumtoxin A in Pain, Spasticity and Functionality-A 5 Years Review.Toxins · 2026Article
- The Adjunctive Role of Botulinum Toxin A in Wound Healing and Scar Management.Aesthetic plastic surgery · 2026Review
- Effects of Botulinum Toxin A on Rosacea-Like Inflammation in an LL-37-Induced Rosacea Mouse Model.Annals of dermatology · 2026Article
- Analyzing the Effect of Extracorporeal Shockwave Therapy after Botulinum Toxin Injection on Calf Muscle Spasticity Improvement in Patients with Multiple Sclerosis - A Randomized Clinical Trial.Advanced biomedical research · 2026Article
- Evaluation of a Cell-Based Potency Assay for Detection of the Potency of TrenibotulinumtoxinEToxins · 2025Article
- Intramuscular Botulinum Toxin for Complex Regional Pain Syndrome: A Narrative Review of Published Cases.Toxins · 2025Review
- Harnessing synaptic vesicle release and recycling with antibody shuttle for targeted delivery of therapeutics to neurons.Molecular therapy. Methods & clinical development · 2025Article
- Influence of the cosmetic use of botulinum toxin type a on temperature measurements using infrared thermography.Archives of dermatological research · 2025Article
- Cryo-EM structure of the botulinum neurotoxin A/SV2B complex and its implications for translocation.Nature communications · 2025Article
- Development of Effective Medical Countermeasures Against the Main Biowarfare Agents: The Importance of Antibodies.Microorganisms · 2024Review
- Botulinum neurotoxin serotype A inhibited ocular angiogenesis through modulating glial activation via SOCS3.Angiogenesis · 2024Article
- The Degradation of Botulinum Neurotoxin Light Chains Using PROTACs.International journal of molecular sciences · 2024Article
- Improving Spasticity by Using Botulin Toxin: An Overview Focusing on Combined Approaches.Brain sciences · 2024Review
- Embracing the Versatility of Botulinum Neurotoxins in Conventional and New Therapeutic Applications.Toxins · 2024Review
- Article
- Article
- New approach to generating of human monoclonal antibodies specific to the proteolytic domain of botulinum neurotoxin A.BioImpacts : BI · 2024Article
- TRPV1BMC immunology · 2023Article
- A DARPin promotes faster onset of botulinum neurotoxin A1 action.Nature communications · 2023Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Botulinum neurotoxin (BoNT) is a major therapeutic agent that is licensed in neurological indications, such as dystonia and spasticity. The BoNT family, which is produced in nature by clostridial bacteria, comprises several pharmacologically distinct proteins with distinct properties. In this review, we present an overview of the current therapeutic landscape and explore the diversity of BoNT proteins as future therapeutics. In recent years, novel indications have emerged in the fields of pain, migraine, overactive bladder, osteoarthritis, and wound healing. The study of biological effects distal to the injection site could provide future opportunities for disease-tailored BoNT therapies. However, there are some challenges in the pharmaceutical development of BoNTs, such as liquid and slow-release BoNT formulations; and, transdermal, transurothelial, and transepithelial delivery. Innovative approaches in the areas of formulation and delivery, together with highly sensitive analytical tools, will be key for the success of next generation BoNT clinical products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.